News

Topadur Pharma AG Strengthens Executive Team Towards IPO

Topadur Pharma AG, a Swiss clinical-stage biotechnology company, today announces the appointments of PD Dr. Matthias Schäfer as Chief Innovation Officer (CIO) and Prof. Dr. Jay Siegel as Chief Research Officer (CRO). Matthias Schäfer is a seasoned international leader, who uniquely combines management skills with in-depth experience in biomedical research from...

read more

FDA Fast Track Designation for ALXN2220 for Depletion of Cardiac ATTR

Zurich, Switzerland - 14.10.2024 Neurimmune today announced that the U.S. Food and Drug Administration (FDA) has granted Alexion, AstraZeneca Rare Disease Fast Track designation for the development of ALXN2220 (formerly NI006) for the treatment of transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-CM is a systemic, progressive and life-threatening disease caused by the deposition of...

read more